SMPDL3b protects against podocyte injury and can be stimulated by Rituximab, a therapeutic agent used in treating recurrent FSGS, possibly by preventing ceramide-1-phosphate production [42,43,44,45]. The gene discussed is SMPDL3B; the disease is focal segmental glomerulosclerosis.